A pharmaceutical company is developing a new drug to treat a rare disease. Initial trials show that patients taking the drug experienced a statistically significant reduction in disease markers compared to a placebo group. The company concludes that the drug is effective and should be approved. Which of the following, if true, would most seriously call into question the company's conclusion?
- AThe reduction in disease markers, while statistically significant, is not large enough to translate into any noticeable improvement in patients' quality of life.
- BThe drug caused mild side effects in 15% of the patients, such as nausea and fatigue.
- CThe trial only included a small number of patients, all of whom were in the early stages of the disease.
- DAnother pharmaceutical company is developing a similar drug that shows even greater reductions in disease markers.
Show answer & explanationAnswer & explanation
Correct answer: A. The reduction in disease markers, while statistically significant, is not large enough to translate into any noticeable improvement in patients' quality of life.
The company concludes the drug is 'effective' based on a statistically significant reduction in disease markers. Option A introduces the concept of 'clinical significance,' arguing that statistical significance alone doesn't guarantee a meaningful real-world benefit. If the reduction isn't noticeable to patients, the drug's 'effectiveness' in a practical sense is questionable, despite the statistical results.
Why the other options are wrong
- B. Side effects are a concern for approval but don't directly challenge the drug's *effectiveness* in reducing disease markers.
- C. A small sample size and specific patient population (early stages) raise questions about generalizability, but don't directly challenge the *effectiveness* for the group studied, or the *meaning* of the observed effect if it were clinically significant.
- D. The existence of a better drug doesn't mean *this* drug is ineffective; it just means it might not be the *best* option.
Clinical Significance vs. Statistical Significance
Statistical significance indicates a result is unlikely due to chance; clinical significance indicates a result has practical, real-world importance for patients or practitioners.
- Statistical significance focuses on probability (p-value).
- Clinical significance focuses on practical impact or magnitude of effect.
- A statistically significant finding may not always be clinically significant, and vice versa.
Memory trick: Does the pill work in the lab AND in real life?